2023-03-06 07:24:32 ET
- Stoke Therapeutics press release ( NASDAQ: STOK ): Q4 GAAP EPS of -$0.65 beats by $0.05 .
- Revenue of $3.27M beats by $0.41M .
- As of December 31, 2022, Stoke had $230.2 million in cash, cash equivalents, marketable securities, and restricted cash. Stoke expects that these resources, together with the proceeds since December 31, 2022 from its Controlled Equity Offering Sales Agreement of $44.7 million, will be sufficient to fund its operations to the end of 2025.
For further details see:
Stoke Therapeutics GAAP EPS of -$0.65 beats by $0.05, revenue of $3.27M beats by $0.41M